• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

21.96 -0.15 (-0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 868,163
Open 22.03
Bid (Size) 21.78 (100)
Ask (Size) 23.00 (500)
Prev. Close 22.11
Today's Range 21.67 - 22.23
52wk Range 14.18 - 28.35
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
April 17, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute

Performance

YTD
-16.5%
-16.5%
1 Month
-0.2%
-0.2%
3 Month
-18.2%
-18.2%
6 Month
-0.3%
-0.3%
1 Year
+48.1%
+48.1%

More News

Read More
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
April 07, 2026
Via Finterra
Topics Economy Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates ↗
February 25, 2026
Via Chartmill
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals ↗
February 06, 2026
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗
January 16, 2026
Via Chartmill
News headline image
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
April 07, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
April 06, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 12, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
March 03, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
March 03, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
March 02, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
February 27, 2026
Via Stocktwits
News headline image
ACADIA (ACAD) Q4 2025 Earnings Call Transcript ↗
February 25, 2026
Via The Motley Fool
Topics Earnings
News headline image
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
February 25, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
February 23, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 04, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug ↗
February 02, 2026
Via Stocktwits
News headline image
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
February 02, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
December 30, 2025
Via MarketMinute
Topics ETFs Economy World Trade

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 21.96
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 04/24/26 04:00 PM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.57B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap